Childhood Midline Tract Carcinoma Involving the NUT Gene (NUT Midline Carcinoma) Treatment (PDQ®)–Health Professional Version

CHILDHOOD MIDLINE TRACT CARCINOMA TREATMENT

SECTIONS

Changes to This Summary (01/26/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Clinical Presentation and Outcome

Added Chau et al. as reference 2.

Treatment of Childhood Midline Tract Carcinoma

Added text to state that in a report from the NUT Midline Carcinoma Registry, 40 patients with primary tumors in the head and neck were evaluable. Two-year overall survival was 30%. The three long-term survivors underwent primary gross-total resection and received adjuvant therapy (cited Chau et al. as reference 2 and level of evidence 3iiA).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Special Considerations for the Treatment of Children With Cancer

Next section >
About This PDQ Summary